Literature DB >> 22129997

Vital signs: HIV prevention through care and treatment--United States.

.   

Abstract

BACKGROUND: An estimated 1.2 million persons in the United States were living with human immunodeficiency virus (HIV) infection in 2008. Improving survival of persons with HIV and reducing transmission involve a continuum of services that includes diagnosis (HIV testing), linkage to and retention in HIV medical care, and ongoing HIV prevention interventions, including appropriately timed antiretroviral therapy (ART).
METHODS: CDC used three surveillance datasets to estimate recent HIV testing and HIV prevalence among U.S. adults by state, and the percentages of HIV-infected adults receiving HIV care for whom ART was prescribed, who achieved viral suppression, and who received prevention counseling from health-care providers. Published data were used to estimate the numbers of persons in the United States living with and diagnosed with HIV and, based on viral load and CD4 laboratory reports, linked to and retained in HIV care.
RESULTS: In 2010, 9.6% of adults had been tested for HIV during the preceding 12 months (range by state: 4.9%-29.8%). Of the estimated 942,000 persons with HIV who were aware of their infection, approximately 77% were linked to care, and 51% remained in care. Among HIV-infected adults in care, 45% received prevention counseling, and 89% were prescribed ART, of whom 77% had viral suppression. Thus, an estimated 28% of all HIV-infected persons in the United States have a suppressed viral load.
CONCLUSIONS: Prevalence of HIV testing and linkage to care are high but warrant continued effort. Increasing the percentages of HIV-infected persons who remain in HIV care, achieve viral suppression, and receive prevention counseling requires additional effort. IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Public health officials and HIV care providers should improve engagement at each step in the continuum of HIV care and monitor progress in every community using laboratory reports of viral load and CD4 test results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129997

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  246 in total

1.  Older African Americans and the HIV Care Continuum: A Systematic Review of the Literature, 2003-2018.

Authors:  Thurka Sangaramoorthy; Amelia Jamison; Typhanye Dyer
Journal:  AIDS Behav       Date:  2019-04

2.  Operational research to improve HIV prevention in the United States.

Authors:  Jeffrey H Herbst; Marlene Glassman; James W Carey; Thomas M Painter; Deborah J Gelaude; Amy M Fasula; Jerris L Raiford; Arin E Freeman; Camilla Harshbarger; Abigail H Viall; David W Purcell
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

3.  Engagement in the HIV Care Continuum among Key Populations in Tijuana, Mexico.

Authors:  Laramie R Smith; Thomas L Patterson; Carlos Magis-Rodriguez; Victoria D Ojeda; Jose Luis Burgos; Sarah A Rojas; María Luisa Zúñiga; Steffanie A Strathdee
Journal:  AIDS Behav       Date:  2016-05

4.  Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.

Authors:  Alison J Hughes; Christine L Mattson; Susan Scheer; Linda Beer; Jacek Skarbinski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

5.  Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality.

Authors:  Michael J Mugavero; Andrew O Westfall; Stephen R Cole; Elvin H Geng; Heidi M Crane; Mari M Kitahata; W Christopher Mathews; Sonia Napravnik; Joseph J Eron; Richard D Moore; Jeanne C Keruly; Kenneth H Mayer; Thomas P Giordano; James L Raper
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

6.  CROI 2018: Advances in Antiretroviral Therapy.

Authors:  Hong-Van Tieu; Barbara S Taylor; Joyce Jones; Timothy J Wilkin
Journal:  Top Antivir Med       Date:  2018-05

Review 7.  Clinically relevant drug-drug interactions between antiretrovirals and antifungals.

Authors:  Ramya Krishna Vadlapatla; Mitesh Patel; Durga K Paturi; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-02-12       Impact factor: 4.481

8.  The association between poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and implications for scale-up of treatment as prevention.

Authors:  Robert H Remien; Curtis Dolezal; Glenn J Wagner; Kathy Goggin; Ira B Wilson; Robert Gross; Marc I Rosen; Jie Shen; Jane M Simoni; Carol E Golin; Julia H Arnsten; David R Bangsberg; Honghu Liu
Journal:  AIDS Behav       Date:  2014-08

9.  Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States.

Authors:  Catherine R Lesko; Stephen R Cole; William C Miller; Daniel Westreich; Joseph J Eron; Adaora A Adimora; Richard D Moore; W Christopher Mathews; Jeffrey N Martin; Daniel R Drozd; Mari M Kitahata; Jessie K Edwards; Michael J Mugavero
Journal:  Clin Infect Dis       Date:  2015-03-12       Impact factor: 9.079

10.  Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.

Authors:  Gary Marks; Lytt I Gardner; Charles E Rose; Anne Zinski; Richard D Moore; Susan Holman; Allan E Rodriguez; Meg Sullivan; Thomas P Giordano
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.